Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2525-2532

  Levine, S ^a   Hernandez, D ^a   Yamanaka, G ^a   Zhang, S ^a   Rose, R ^a   Weinheimer, S ^a   Colonno, R J ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; ENTECAVIR; LAMIVUDINE; ANTIVIRUS AGENT; CAPSID PROTEIN; DNA DIRECTED DNA POLYMERASE; DRUG DERIVATIVE; GUANINE; RECOMBINANT PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG EFFICACY; ENZYME INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS MUTATION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; GENETICS; KINETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VIRUS GENE; VIRUS GENOME;

ANTIVIRAL AGENTS; BLOTTING, SOUTHERN; CAPSID PROTEINS; CELLS, CULTURED; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; GENES, VIRAL; GENOME, VIRAL; GUANINE; HEPATITIS B VIRUS; HUMAN; KINETICS; LAMIVUDINE; PHOSPHORYLATION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION; HUMANS;

EID: 0035991863     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2525-2532.2002     Document Type: Article

References (32)

1. Identification and characterization of mutations in hepatitis B resistant to lamivudine
2. Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA
3. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
4. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine and emtricitabine
5. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
6. Hepatitis B virus replication in human HepG2 cells mediate by hepatitis B virus recombinant baculovirus
7. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection
8. Lamivudine as initial treatment for chronic hepatitis B in the United States
9. A new graphical procedure for estimating enzyme kinetic parameters
10. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
11. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription
12. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus
13. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
14. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B
15. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
16. Clinical pharmacokinetics of lamivudine
17. The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells
18. Rapid and efficient site-specific mutagenesis without phenotypic selection
19. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA
20. A phase II study of entecavir vs. lamivudine in adults with chronic hepatitis B
21. A one year trial of lamivudine for chronic hepatitis B
22. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
23. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
24. Potent efficacy observed with entecavir (BMS-200475) in duck model of hepatitis B virus replication
25. Lamivudine therapy of WHV-infected woodchucks
26. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
27. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
28. The polymerase L528M mutation cooperates with nucleotide binding site mutations, increasing hepatitis B virus replication and drug resistance
29. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells
30. In vitro inhibition of hepadnavirus polymerase by the triphosphates of BMS-200745 and lobucavir
31. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
32. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B